Radiotherapy for Unfavorable-risk Prostate Cancer: Biologic Dose Escalation, Fewer Fractions, or Both?

被引：0
|
作者：
Ong, Wee Loon [1 ,2 ]
Loblaw, Andrew [3 ,4 ]
机构：
[1] Monash Univ, Sch Translat Med, Alfred Hlth Radiat Oncol, Melbourne, Australia
[2] Monash Univ, Sch Publ Hlth & Prevent Med, Prostate Canc Outcomes Registry Australia & New Ze, Melbourne, Australia
[3] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Toronto, ON, Canada
[4] Univ Toronto, Inst Hlth Policy Measurement & Evaluat, Toronto, ON, Canada
来源：
EUROPEAN UROLOGY | 2025年 / 87卷 / 03期
关键词：
STEREOTACTIC BODY RADIOTHERAPY; OUTCOMES;
D O I：
10.1016/j.eururo.2024.09.032
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：324 / 325
页数：2
相关论文
共 50 条
  • [1] Optimal Radiotherapy for Unfavorable-risk Prostate Cancer
    Crook, Juanita
    EUROPEAN UROLOGY, 2017, 72 (05) : 745 - 746
  • [2] Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates
    Sorce, Gabriele
    Flammia, Rocco Simone
    Hoeh, Benedikt
    Chierigo, Francesco
    Hohenhorst, Lukas
    Panunzio, Andrea
    Stabile, Armando
    Gandaglia, Giorgio
    Tian, Zhe
    Tilki, Derya
    Terrone, Carlo
    Gallucci, Michele
    Chun, Felix K. H.
    Antonelli, Alessandro
    Saad, Fred
    Shariat, Shahrokh F.
    Montorsi, Francesco
    Briganti, Alberto
    Karakiewicz, Pierre, I
    PROSTATE, 2022, 82 (10): : 1040 - 1050
  • [3] Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer
    Johnson, Skyler B.
    Lester-Coll, Nataniel H.
    Kelly, Jacqueline R.
    Kann, Benjamin H.
    Yu, James B.
    Nath, Sameer K.
    EUROPEAN UROLOGY, 2017, 72 (05) : 738 - 744
  • [4] Dose escalation radiotherapy of prostate cancer
    Widmark, A
    RADIOTHERAPY AND ONCOLOGY, 2005, 76 : S83 - S84
  • [5] Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer
    Yang, David D.
    Mahal, Brandon A.
    Muralidhar, Vinayak
    Boldbaatar, Ninjin
    Labe, Shelby A.
    Nezolosky, Michelle D.
    Vastola, Marie E.
    Beard, Clair J.
    Martin, Neil E.
    Mouw, Kent W.
    Orio, Peter F., III
    King, Martin T.
    Nguyen, Paul L.
    CANCER, 2017, 123 (24) : 4832 - 4840
  • [6] Metastatic progression following multimodal therapy for unfavorable-risk prostate cancer
    Guy, David
    Glicksman, Rachel
    Buckley, Roger
    Cheung, Patrick
    Chung, Hans
    Flax, Stanley
    Hajek, David
    Loblaw, Andrew
    Morton, Gerard
    Noakes, Jeffery
    Spevack, Les
    Chin, Joseph L. K.
    Rodrigues, George
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2022, 16 (04): : E220 - E226
  • [7] The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer
    Schneider, Uwe
    Lomax, Antony
    Besserer, Juergen
    Pemler, Peter
    Lombriser, Norbert
    Kaser-Hotz, Barbara
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (03): : 892 - 897
  • [8] The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer
    Schneider, U
    Lomax, A
    Besserer, J
    Lombriser, N
    Pemler, P
    Ross, D
    Kaser-Hotz, B
    RADIOTHERAPY AND ONCOLOGY, 2006, 78 : S54 - S54
  • [9] Hazards of dose escalation in prostate cancer radiotherapy
    Kuban, D
    Pollack, A
    Huang, E
    Levy, L
    Dong, L
    Starkschall, G
    Rosen, I
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (05): : 1260 - 1268
  • [10] Percent positive biopsy cores and the risk of death from prostate cancer in men with unfavorable-risk prostate cancer
    Phillips, John G.
    Chen, Ming-Hui
    Zhang, Danjie
    Loffredo, Marian
    Kantoff, Philip W.
    D'Amico, Anthony V.
    JOURNAL OF RADIATION ONCOLOGY, 2014, 3 (03) : 307 - 312
12345